Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Co Diagnostics Inc's Business Segments
Co Diagnostics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Non-US Product
Total Revenue
$ 0
Countrys Reported
1
Revenue Share by Reportable Segment - FY
- Non-US Product75.9%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Non-US Product | $ 0 | 75.9% |
Revenue Share by Country - FY
- US55.5%
Revenue by Geographic Country - FY
| Country | Revenue (Millions) | % of Total |
|---|---|---|
| US | $ 0 | 55.5% |
Revenue by Product & Service Category - FY
- Product0%
- Grant0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 0 | - |
| Grant | - | 0% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Non-US Product75.9%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Non-US Product | $ 0 | 75.9% |
Description of Co Diagnostics Inc
Co Diagnostics Inc is a molecular diagnostics company that focuses on developing, manufacturing, and marketing innovative diagnostic tests for infectious diseases and other molecular markers. The company is headquartered in Salt Lake City, Utah, and is traded on the Nasdaq stock exchange under the ticker symbol CODX.
Co Diagnostics Inc utilizes its proprietary CoPrimer technology platform, which allows for highly accurate and specific detection of target nucleic acids. This innovative technology enables the company to provide fast, reliable, and cost-effective diagnostic solutions.
The company's product portfolio includes a range of diagnostic tests for various infectious diseases, such as COVID-19, tuberculosis, malaria, dengue fever, Zika virus, and HPV, among others. These tests are designed to detect and identify the specific genetic material of the pathogen causing the disease, offering clinicians and healthcare professionals valuable information for accurate diagnosis and appropriate treatment.
One of the key highlights of Co Diagnostics Inc is its COVID-19 diagnostic test, which was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) in April 2020. The test utilizes the CoPrimer technology to detect the presence of SARS-CoV-2, the virus causing COVID-19, in respiratory samples. The test has been widely adopted by healthcare providers, laboratories, and governments worldwide due to its high sensitivity and specificity.
Co Diagnostics Inc has established collaborations and partnerships with various organizations and institutions to further advance its diagnostic technologies and expand its market reach. These partnerships include strategic alliances with manufacturing, distribution, and commercialization partners, as well as research collaborations with universities, government agencies, and other diagnostic companies.
In addition to its diagnostic tests, Co Diagnostics Inc also offers custom development services to help organizations and researchers design and optimize their own diagnostic solutions using the CoPrimer platform. This service allows for tailored testing solutions for a wide range of applications, including clinical diagnostics, agriculture, veterinary medicine, and environmental testing.
The company places a strong emphasis on quality control and regulatory compliance, ensuring that its diagnostic tests meet the highest standards of accuracy and reliability. Co Diagnostics Inc has obtained ISO 13485 certification, which demonstrates its commitment to quality management systems for medical devices.
Overall, Co Diagnostics Inc is a leading molecular diagnostics company that is revolutionizing the field with its innovative CoPrimer technology platform. With its extensive range of diagnostic tests, strategic partnerships, and commitment to delivering accurate and accessible diagnostic solutions, the company is well-positioned for continued growth and success in the global diagnostics market.
Co Diagnostics Inc utilizes its proprietary CoPrimer technology platform, which allows for highly accurate and specific detection of target nucleic acids. This innovative technology enables the company to provide fast, reliable, and cost-effective diagnostic solutions.
The company's product portfolio includes a range of diagnostic tests for various infectious diseases, such as COVID-19, tuberculosis, malaria, dengue fever, Zika virus, and HPV, among others. These tests are designed to detect and identify the specific genetic material of the pathogen causing the disease, offering clinicians and healthcare professionals valuable information for accurate diagnosis and appropriate treatment.
One of the key highlights of Co Diagnostics Inc is its COVID-19 diagnostic test, which was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) in April 2020. The test utilizes the CoPrimer technology to detect the presence of SARS-CoV-2, the virus causing COVID-19, in respiratory samples. The test has been widely adopted by healthcare providers, laboratories, and governments worldwide due to its high sensitivity and specificity.
Co Diagnostics Inc has established collaborations and partnerships with various organizations and institutions to further advance its diagnostic technologies and expand its market reach. These partnerships include strategic alliances with manufacturing, distribution, and commercialization partners, as well as research collaborations with universities, government agencies, and other diagnostic companies.
In addition to its diagnostic tests, Co Diagnostics Inc also offers custom development services to help organizations and researchers design and optimize their own diagnostic solutions using the CoPrimer platform. This service allows for tailored testing solutions for a wide range of applications, including clinical diagnostics, agriculture, veterinary medicine, and environmental testing.
The company places a strong emphasis on quality control and regulatory compliance, ensuring that its diagnostic tests meet the highest standards of accuracy and reliability. Co Diagnostics Inc has obtained ISO 13485 certification, which demonstrates its commitment to quality management systems for medical devices.
Overall, Co Diagnostics Inc is a leading molecular diagnostics company that is revolutionizing the field with its innovative CoPrimer technology platform. With its extensive range of diagnostic tests, strategic partnerships, and commitment to delivering accurate and accessible diagnostic solutions, the company is well-positioned for continued growth and success in the global diagnostics market.
Co-Diagnostics, Inc. is a biotechnology company focused on developing and commercializing molecular diagnostic technology. The company is primarily known for its proprietary platform that allows for the creation of highly specific and sensitive tests for a variety of diseases, particularly infectious diseases.
Segments
Co-Diagnostics operates primarily in the diagnostics segment of the healthcare field, with a focus on molecular diagnostics. This segment is characterized by the development of tests that utilize advanced techniques to analyze genetic material from pathogens, which can provide rapid and accurate information regarding infections.
1. Infectious Disease Diagnostics: This is one of the key segments for Co-Diagnostics. Their tests are designed to detect the presence of viral, bacterial, and parasitic pathogens. This is particularly relevant in light of global health challenges such as the COVID-19 pandemic and other outbreaks of infectious diseases.
2. Genetic Testing: Beyond infectious diseases, Co-Diagnostics is also involved in genetic testing, which can aid in the diagnosis of genetic disorders and conditions. This includes tests for inherited diseases and conditions, as well as pharmacogenomics to tailor medical treatments based on genetic profiles.
3. Research and Development: A significant aspect of Co-Diagnostics business model includes continuous research and development to enhance existing tests and develop new ones. This segment focuses on improving diagnostic accuracy, sensitivity, and speed, while also working on tests for emerging infectious diseases.
Products
Co-Diagnostics offers a range of proprietary products that are based on its patented CoPrimer™ technology, which enhances the specificity and sensitivity of molecular tests. Products include:
1. PCR Tests: The company is well-known for its polymerase chain reaction (PCR) tests, which are utilized to detect the presence of specific nucleic acids in microorganisms. This technology is crucial for accurately diagnosing infections, including those caused by viruses, bacteria, and parasites.
2. COVID-19 Testing: In response to the pandemic, Co-Diagnostics developed tests specifically for the detection of SARS-CoV-2, the virus responsible for COVID-19. These tests have been crucial for public health measures and have been widely utilized in various settings, including healthcare and commercial institutions.
3. Vector-Borne Disease Tests: Co-Diagnostics also focuses on tests for diseases transmitted by vectors, such as mosquitoes and ticks. These tests provide essential data in regions where such diseases are prevalent, enabling timely diagnosis and treatment.
4. Infectious Disease Panels: The company offers panels that can simultaneously test for multiple pathogens, streamlining the diagnostic process for clinicians and improving patient care. These panels are especially useful in situations where multiple infectious diseases might be present.
5. Laboratory Services: Alongside their diagnostic products, Co-Diagnostics also provides laboratory services to support testing for healthcare institutions and other organizations. This can involve the processing of samples and providing comprehensive test results.
Services
Co-Diagnostics provides various services that complement its product offerings and enhance its customer support capabilities.
1. Technical Support and Training: The company offers training programs for laboratory personnel and healthcare providers on the proper use and implementation of their diagnostic tests. This ensures that end-users can achieve optimal results and understand the nuances of product use.
2. Custom Assay Development: Recognizing the diverse needs of various healthcare providers, Co-Diagnostics offers custom assay development services. This allows clients to have tailored tests developed for specific pathogens or conditions that may not be covered by off-the-shelf products.
3. Regulatory Support: Navigating the regulatory landscape is crucial in the diagnostics field, and Co-Diagnostics provides assistance to clients in achieving necessary clearances and approvals for their diagnostic products, ensuring compliance with health regulations.
4. Partnerships and Collaborations: Co-Diagnostics seeks to establish partnerships with academic institutions, research organizations, and public health bodies to enhance its product offerings and expand its reach into new markets.
In summary, Co-Diagnostics, Inc. operates in the molecular diagnostics sector, providing a range of diagnostic products and services primarily focused on infectious diseases, genetic testing, and R&D. Their offerings are grounded in advanced technology designed to improve diagnostic accuracy and efficiency, ultimately aimed at enhancing patient care and public health outcomes.
Segments
Co-Diagnostics operates primarily in the diagnostics segment of the healthcare field, with a focus on molecular diagnostics. This segment is characterized by the development of tests that utilize advanced techniques to analyze genetic material from pathogens, which can provide rapid and accurate information regarding infections.
1. Infectious Disease Diagnostics: This is one of the key segments for Co-Diagnostics. Their tests are designed to detect the presence of viral, bacterial, and parasitic pathogens. This is particularly relevant in light of global health challenges such as the COVID-19 pandemic and other outbreaks of infectious diseases.
2. Genetic Testing: Beyond infectious diseases, Co-Diagnostics is also involved in genetic testing, which can aid in the diagnosis of genetic disorders and conditions. This includes tests for inherited diseases and conditions, as well as pharmacogenomics to tailor medical treatments based on genetic profiles.
3. Research and Development: A significant aspect of Co-Diagnostics business model includes continuous research and development to enhance existing tests and develop new ones. This segment focuses on improving diagnostic accuracy, sensitivity, and speed, while also working on tests for emerging infectious diseases.
Products
Co-Diagnostics offers a range of proprietary products that are based on its patented CoPrimer™ technology, which enhances the specificity and sensitivity of molecular tests. Products include:
1. PCR Tests: The company is well-known for its polymerase chain reaction (PCR) tests, which are utilized to detect the presence of specific nucleic acids in microorganisms. This technology is crucial for accurately diagnosing infections, including those caused by viruses, bacteria, and parasites.
2. COVID-19 Testing: In response to the pandemic, Co-Diagnostics developed tests specifically for the detection of SARS-CoV-2, the virus responsible for COVID-19. These tests have been crucial for public health measures and have been widely utilized in various settings, including healthcare and commercial institutions.
3. Vector-Borne Disease Tests: Co-Diagnostics also focuses on tests for diseases transmitted by vectors, such as mosquitoes and ticks. These tests provide essential data in regions where such diseases are prevalent, enabling timely diagnosis and treatment.
4. Infectious Disease Panels: The company offers panels that can simultaneously test for multiple pathogens, streamlining the diagnostic process for clinicians and improving patient care. These panels are especially useful in situations where multiple infectious diseases might be present.
5. Laboratory Services: Alongside their diagnostic products, Co-Diagnostics also provides laboratory services to support testing for healthcare institutions and other organizations. This can involve the processing of samples and providing comprehensive test results.
Services
Co-Diagnostics provides various services that complement its product offerings and enhance its customer support capabilities.
1. Technical Support and Training: The company offers training programs for laboratory personnel and healthcare providers on the proper use and implementation of their diagnostic tests. This ensures that end-users can achieve optimal results and understand the nuances of product use.
2. Custom Assay Development: Recognizing the diverse needs of various healthcare providers, Co-Diagnostics offers custom assay development services. This allows clients to have tailored tests developed for specific pathogens or conditions that may not be covered by off-the-shelf products.
3. Regulatory Support: Navigating the regulatory landscape is crucial in the diagnostics field, and Co-Diagnostics provides assistance to clients in achieving necessary clearances and approvals for their diagnostic products, ensuring compliance with health regulations.
4. Partnerships and Collaborations: Co-Diagnostics seeks to establish partnerships with academic institutions, research organizations, and public health bodies to enhance its product offerings and expand its reach into new markets.
In summary, Co-Diagnostics, Inc. operates in the molecular diagnostics sector, providing a range of diagnostic products and services primarily focused on infectious diseases, genetic testing, and R&D. Their offerings are grounded in advanced technology designed to improve diagnostic accuracy and efficiency, ultimately aimed at enhancing patient care and public health outcomes.